Lisa G. Wolf - 18 Sep 2026 Form 4 Insider Report for Valion Bio, Inc. (VBIO)

Reporting relationship: COO & CFO
Issuer ticker: VBIO
Reported as of: 18 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Sep 2026, 16:45:35 UTC
Prior SEC filing: 18 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Lisa Wolf

Filing notes and source

Key filing fact

Lisa G. Wolf filed Form 4 for Valion Bio, Inc. (VBIO) on 24 Sep 2026.

Key facts

This page summarizes Lisa G. Wolf's Form 4 filing for Valion Bio, Inc. (VBIO).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 24 Sep 2026, 16:45.

Change

Previous filing in this sequence was filed on 18 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001861556 Primary reporting owner

Wolf Lisa G

Relationship: COO & CFO
Address: 1305 E. HOUSTON ST., BLDG 1, STE. 311, SAN ANTONIO
Signature: /s/ Lisa Wolf
Signature date: 24 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VBIO transaction

Common Stock

Options Exercise

Transaction value
Shares: +4
Change %: +16%
Price
Shares after: 29
Date: 18 Sep 2026
Ownership: Direct
Footnotes: F1, F3

VBIO transaction

Common Stock

Tax liability

Transaction value
Shares: -2
Change %: -6.9%
Price: $2.12^*
Shares after: 27
Date: 18 Sep 2026
Ownership: Direct
Footnotes: F2, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VBIO transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -4
Change %: -17%
Price: $0.000000^*
Shares after: 19
Date: 18 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4
Exercise price
Footnotes: F1, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Each Restricted Stock Unit is convertible into one share of Common Stock.

Footnote F2

The Reporting Person forfeited 2 shares of Common Stock upon vesting and settlement of 4 outstanding Restricted Stock Units to cover tax withholdings, using the market price of the Issuer's Common Stock at the time of forfeiture.

Footnote F3

Fifty percent (50%) of the Restricted Stock Units vested upon the one (1) year anniversary of the date of grant, December 18, 2024 (the "Vesting Commencement Date"), and the balance of the Restricted Stock Units will be vested in a series of eight (8) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that one hundred percent (100%) of the Restricted Stock Units shall have vested on the third anniversary of the Vesting Commencement Date.

Footnote F4

These numbers have been adjusted to reflect the reverse stock split of the Common Stock of Valion Bio, Inc., which underwent a reverse stock split at a ratio of 1-for-25 on August 31, 2026.